These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 25838293)

  • 1. Perioperative chemotherapy with ifosfamide and doxorubicin for high-grade soft tissue sarcomas in the extremities (JCOG0304).
    Tanaka K; Mizusawa J; Fukuda H; Araki N; Chuman H; Takahashi M; Ozaki T; Hiruma T; Tsuchiya H; Morioka H; Hatano H; Iwamoto Y
    Jpn J Clin Oncol; 2015 Jun; 45(6):555-61. PubMed ID: 25838293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ten-year follow-up results of perioperative chemotherapy with doxorubicin and ifosfamide for high-grade soft-tissue sarcoma of the extremities: Japan Clinical Oncology Group study JCOG0304.
    Tanaka K; Mizusawa J; Naka N; Kawai A; Katagiri H; Hiruma T; Matsumoto Y; Tsuchiya H; Nakayama R; Hatano H; Emori M; Watanuki M; Yoshida Y; Okamoto T; Abe S; Asanuma K; Yokoyama R; Hiraga H; Yonemoto T; Morii T; Ae K; Nagano A; Yoshikawa H; Fukuda H; Ozaki T; Iwamoto Y
    BMC Cancer; 2019 Sep; 19(1):890. PubMed ID: 31492159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
    Gronchi A; Ferrari S; Quagliuolo V; Broto JM; Pousa AL; Grignani G; Basso U; Blay JY; Tendero O; Beveridge RD; Ferraresi V; Lugowska I; Merlo DF; Fontana V; Marchesi E; Donati DM; Palassini E; Palmerini E; De Sanctis R; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Casali PG
    Lancet Oncol; 2017 Jun; 18(6):812-822. PubMed ID: 28499583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative and postoperative chemotherapy with ifosfamide and adriamycin for adult high-grade soft-tissue sarcomas in the extremities: Japan Clinical Oncology Group Study JCOG0304.
    Tanaka K; Kawamoto H; Saito I; Yoshimura K; Fukuda H; Iwamoto Y
    Jpn J Clin Oncol; 2009 Apr; 39(4):271-3. PubMed ID: 19155282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Standardization of evaluation method and prognostic significance of histological response to preoperative chemotherapy in high-grade non-round cell soft tissue sarcomas.
    Oda Y; Tanaka K; Hirose T; Hasegawa T; Hiruta N; Hisaoka M; Yoshimoto M; Otsuka H; Bekki H; Ishii T; Endo M; Kunisada T; Hiruma T; Tsuchiya H; Katagiri H; Matsumoto Y; Kawai A; Nakayama R; Kawashima H; Takenaka S; Emori M; Watanuki M; Yoshida Y; Okamoto T; Mizusawa J; Fukuda H; Ozaki T; Iwamoto Y; Nojima T
    BMC Cancer; 2022 Jan; 22(1):94. PubMed ID: 35062915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
    Lorigan P; Verweij J; Papai Z; Rodenhuis S; Le Cesne A; Leahy MG; Radford JA; Van Glabbeke MM; Kirkpatrick A; Hogendoorn PC; Blay JY;
    J Clin Oncol; 2007 Jul; 25(21):3144-50. PubMed ID: 17634494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group.
    Le Cesne A; Judson I; Crowther D; Rodenhuis S; Keizer HJ; Van Hoesel Q; Blay JY; Frisch J; Van Glabbeke M; Hermans C; Van Oosterom A; Tursz T; Verweij J
    J Clin Oncol; 2000 Jul; 18(14):2676-84. PubMed ID: 10894866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paediatric non-rhabdomyosarcoma soft tissue sarcomas: the prospective NRSTS 2005 study by the European Pediatric Soft Tissue Sarcoma Study Group (EpSSG).
    Ferrari A; van Noesel MM; Brennan B; Zanetti I; Corradini N; Casanova M; Berlanga P; Merks JHM; Alaggio R; Schifflers S; Ramirez-Villar GL; Giraudo C; Burrieza GG; Safwat A; Bisogno G; De Salvo GL; Orbach D
    Lancet Child Adolesc Health; 2021 Aug; 5(8):546-558. PubMed ID: 34214481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized phase II/III trial of perioperative chemotherapy with adriamycin plus ifosfamide versus gemcitabine plus docetaxel for high-grade soft tissue sarcoma: Japan Clinical Oncology Group Study JCOG1306.
    Kataoka K; Tanaka K; Mizusawa J; Kimura A; Hiraga H; Kawai A; Matsunobu T; Matsumine A; Araki N; Oda Y; Fukuda H; Iwamoto Y;
    Jpn J Clin Oncol; 2014 Aug; 44(8):765-9. PubMed ID: 24916336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Impact of Perioperative Chemotherapy Timing in Conjunction With Postoperative External-Beam Radiation Therapy on Extremity Soft-Tissue Sarcomas Outcome.
    Mahmoud O; Dosch A; Kwon D; Pitcher JD; Conway S; Benedetto P; Fernandez G; Trent J; Temple HT; Wolfson AH
    Am J Clin Oncol; 2016 Oct; 39(5):528-34. PubMed ID: 24879472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternating sequential chemotherapy with high-dose ifosfamide and doxorubicin/cyclophosphamide for adult non-small round cell soft tissue sarcomas.
    Kawai A; Umeda T; Wada T; Ihara K; Isu K; Abe S; Ishii T; Sugiura H; Araki N; Ozaki T; Yabe H; Hasegawa T; Tsugane S; Beppu Y;
    J Orthop Sci; 2005 May; 10(3):258-63. PubMed ID: 15928887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
    Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT;
    Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children's Oncology Group prospective study.
    Spunt SL; Million L; Chi YY; Anderson J; Tian J; Hibbitts E; Coffin C; McCarville MB; Randall RL; Parham DM; Black JO; Kao SC; Hayes-Jordan A; Wolden S; Laurie F; Speights R; Kawashima E; Skapek SX; Meyer W; Pappo AS; Hawkins DS
    Lancet Oncol; 2020 Jan; 21(1):145-161. PubMed ID: 31786124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial.
    Woll PJ; Reichardt P; Le Cesne A; Bonvalot S; Azzarelli A; Hoekstra HJ; Leahy M; Van Coevorden F; Verweij J; Hogendoorn PC; Ouali M; Marreaud S; Bramwell VH; Hohenberger P;
    Lancet Oncol; 2012 Oct; 13(10):1045-54. PubMed ID: 22954508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Five-year results from a Scandinavian sarcoma group study (SSG XIII) of adjuvant chemotherapy combined with accelerated radiotherapy in high-risk soft tissue sarcoma of extremities and trunk wall.
    Jebsen NL; Bruland ØS; Eriksson M; Engellau J; Turesson I; Folin A; Trovik CS; Hall KS
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1359-66. PubMed ID: 20933339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The activity of the Bone and Soft Tissue Tumor Study Group of the Japan Clinical Oncology Group.
    Iwamoto Y; Tanaka K
    Jpn J Clin Oncol; 2012 Jun; 42(6):467-70. PubMed ID: 22628611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study evaluating neo-/adjuvant EIA chemotherapy, surgical resection and radiotherapy in high-risk soft tissue sarcoma.
    Schmitt T; Lehner B; Kasper B; Bischof M; Roeder F; Dietrich S; Dimitrakopoulou-Strauss A; Strauss LG; Mechtersheimer G; Wuchter P; Ho AD; Egerer G
    BMC Cancer; 2011 Dec; 11():510. PubMed ID: 22152120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant Interdigitated Chemoradiotherapy Using Mesna, Doxorubicin, and Ifosfamide for Large, High-grade, Soft Tissue Sarcomas of the Extremity: Improved Efficacy and Reduced Toxicity.
    Chowdhary M; Sen N; Jeans EB; Miller L; Batus M; Gitelis S; Wang D; Abrams RA
    Am J Clin Oncol; 2019 Jan; 42(1):1-5. PubMed ID: 29782358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Santoro A; Tursz T; Mouridsen H; Verweij J; Steward W; Somers R; Buesa J; Casali P; Spooner D; Rankin E
    J Clin Oncol; 1995 Jul; 13(7):1537-45. PubMed ID: 7602342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant chemoradiotherapy for patients with high-risk extremity and truncal sarcomas: a 10-year single institution retrospective study.
    Look Hong NJ; Hornicek FJ; Harmon DC; Choy E; Chen YL; Yoon SS; Nielsen GP; Szymonifka J; Yeap BY; DeLaney TF; Mullen JT
    Eur J Cancer; 2013 Mar; 49(4):875-83. PubMed ID: 23092789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.